Daniel Eiger

8PUBLICATIONS
26CO-AUTHORS
Environmental epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 08, 2023
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.

Diogo Martins-Branco, Marie Kassapian, Véronique Debien

|Jun 28, 2022
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.

Jens Huober, Carlos H Barrios, Naoki Niikura

|Jun 10, 2022
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer.

Chau Dang, Michael S Ewer, Suzette Delaloge

|Apr 03, 2021
The Exciting New Field of HER2-Low Breast Cancer Treatment.

Daniel Eiger, Elisa Agostinetto, Rita Saúde-Conde

|Feb 22, 2020
Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials.

Daniel Eiger, Maria Alice Franzoi, Noam Pondé

|Aug 02, 2018
Complete lymphadenectomy following positive sentinel lymph node biopsy in cutaneous melanoma: a critical review.

Daniel Eiger, Daniel Arcuschin de Oliveira, Renato Leão de Oliveira

Pageof 2

Frequent Collaborators

4 joint publications

Evandro de Azambuja

1 joint publications

Daniel Arcuschin de Oliveira

1 joint publications

Renato Leão de Oliveira

1 joint publications

Murilo Costa Sousa